Sub-family selective actions in the ability of Erk2 MAP kinase to phosphorylate and regulate the activity of PDE4 cyclic AMP-specific phosphodiesterases

British Journal of Pharmacology

Volumn 131, Issue 4, 2000, Pages 811-819

  Baillie, George S ^a   MacKenzie, Simon J ^a   McPhee, Ian ^a   Houslay, Miles D ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cyclic AMP phosphodiesterase; Erk2; P42 MAP kinase; PDE4; Phosphorylation; Rolipram

Indexed keywords

ASPARTIC ACID; EPIDERMAL GROWTH FACTOR; ISOENZYME; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHODIESTERASE IV; SERINE;

ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME SPECIFICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; SIGNAL TRANSDUCTION;

EID: 0035224063     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703636     Document Type: Article

References (63)

1. AHMAD, F., GAO, G., LING MEI, W., LANDSTROM, T.R., DEGERMAN, E., PIERCE, J.H. & MANGANIELLO, V.C. (1999). IL-3 and IL-4 activate cyclic nucleotide phosphodiesterases 3 (PDE3) and 4 (PDE4) by different mechanisms in FDCP2 myeloid cells. J. Immunol., 162, 4864-4875.
2. ALVAREZ, E., NORTHWOOD, I.C., GONZALEZ, F.A., LATOUR, D.A., SETH, A., ABATE, C. CURRAN, T. & DAVIS, R.J. (1991). Pro-Leu-Ser/Thr-Pro is a consensus primary sequence for substrate protein phosphorylation: characterization of the phosphorylation of c-myc and c-jun proteins by an epidermal growth factor receptor threonine 669 protein kinase. J. Biol. Chem., 266, 15277-15285.
3. ALVAREZ, R., SETTE, C., YANG, D., EGLEN, R.M., WILHELM, R., SHELTON, E.R. & CONTI, M. (1995). Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3. Mol. Pharmacol., 48, 616-622.
4. BEARD, M.B., OLSEN, A.E., JONES, R.E., ERDOGAN, S., HOUSLAY, M.D. & BOLGER, G.B. (2000). UCR1 and UCR2 domains unique to the cAMP-specific phosphodiesterase (PDE4) family form a discrete module via electrostatic interactions. J. Biol. Chem., 275, 10349-10358.
5. BEAVO, J.A. (1995). Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev., 75, 725-748.
6. BLANCO-APARICIO, C., TORRES, J. & PULIDO, R. (1999). A novel regulatory mechanism of MAP kinase activation and nuclear translocation mediated by PKA and the PTP-SL tyrosine phosphatase. J. Cell Biol., 147, 1129-1135.
7. BLUMER, K.J. & JOHNSON, G.L. (1994). Diversity in function and regulation of MAP kinase pathways. Trends Biochem. Sci., 19, 236-240.
8. BOLGER, G. (1994). Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. Cell. Signal., 6, 851-859.
9. BOLGER, G., MICHAELI, T. MARTINS, T. ST. JOHN, T., STEINER, B., RODGERS, L., RIGGS, M., WIGLER, M. & FERGUSON, K. (1993). A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol. Cell. Biol., 13, 6558-6571.
10. BOLGER, G.B., ERDOGAN, S., JONES, R.E., LOUGHNEY, K., SCOTLAND, G., HOFFMAN, R., WILKINSON, I., FARRELL, C. & HOUSLAY, M.D. (1997). Characterisation of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. Biochem. J., 328, 539-548.
11. BOLGER, G.B., MCPHEE, I. & HOUSLAY, M.D. (1996). Alternative splicing of cAMP-specific phosphodiesterase mRNA transcripts: characterization of a novel tissue-specific isoform, RNPDE4A8. J. Biol. Chem., 271, 1065-1071.
12. BRADFORD, M. (1976). Protein determination in biological samples. Anal. Biochem., 72, 248-254.
13. ras-directed activation of extracellular signal-regulated kinase 2 and phosphorylation of mSos nucleotide exchange factor. EMBO J., 12, 4211-4220.
14. CAVALLA, D. & FRITH, R. (1995). Phosphodiesterase IV inhibitors: structural diversity and therapeutic potential in asthma. Curr. Opin. Med. Chem., 2, 561-572.
15. COLLEDGE, M. & SCOTT, J.D. (1999). AKAPs: prom structure to function. Trends Cell Biol., 9, 216-221.
16. CONTI, M. & JIN, S.L.C. (1999). The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res., 63, 1-38.
17. COOK, S.J. & MCCORMICK, F. (1993). Inhibition by cAMP of ras-dependent activation of raf. Science, 262, 1069-1072.
18. DENT, G. & GIEMBYCZ, M.A. (1995). Selective phosphodiesterase inhibitors in the therapy of asthma. Clin. Immunother., 3, 423-437.
19. GIEMBYCZ, M.A. (1996). Phosphodiesterase 4 and tolerance to beta2-adrenoceptor agonists in asthma. Trends Pharmacol. Sci., 17, 331-336.
20. GRAVES, L.M., BORNFELDT, K.E., RAINES, E.W., POTTS, B.C., MACDONALD, S.G., ROSS, R. & KREBS, E.G. (1993). Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc. Natl. Acad. Sci. U.S.A., 90, 10300-10304.
21. HAFNER, S., ADLER, H.S. & MISCHAK, H. (1994). Mechanism of inhibition of Raf-1 by protein kinase A. Mol. Cell Biol., 14, 6696-6703.
22. HERRERA-VELIT, P., KNUTSON, K.L. & REINER, N.E. (1997). Phosphatidylinositol 3-kinase-dependent activation of protein kinase C-zeta in bacterial lipopolysaccharide-treated human monocytes. J. Biol. Chem., 272, 16445-16452.
23. lyn and phosphatidylinositol 3-kinase in human monocytes. J. Immunol., 156, 1157-1165.
24. HEYWORTH, C.M. & HOUSLAY, M.D. (1983). Challenge of hepatocytes by glucagon triggers a rapid modulation of adenylate cyclase activity in isolated membranes. Biochem. J., 214, 93-98.
25. 579. EMBO J., 18, 893-903.
26. HOFFMANN, R., WILKINSON, I.R., MCCALLUM, J.F., ENGELS, P. & HOUSLAY, M.D. (1998). cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model. Biochem. J., 333, 139-149.
27. HOUSLAY, M.D. & MILLIGAN, G. (1997). Tailoring cAMP signalling responses through isoform multiplicity. Trends Biochem. Sci., 22, 217-224.
28. HOUSLAY, M.D., SULLIVAN, M. & BOLGER, G.B. (1998). The multi-enzyme PDE4 cyclic AMP specific phosphodiesterase family: intracellular targeting, regulation and selective inhibition by compounds exerting anti-inflammatory and anti-depressant actions. Adv. Pharmacol., 44, 225-342.
29. HUSTON, E., LUMB, S., RUSSELL, A., CATTERALL, C., ROSS, A.H., STEELE, M.R., BOLGER, G.B., PERRY, M., OWENS, R. & HOUSLAY, M.D. (1997). Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cyclic AMP specific phosphodiesterase, HSPDE4B3. Biochem. J., 328, 549-558.
30. HUSTON, E., POOLEY, L., JULIEN, J., SCOTLAND, G., MCPHEE, I., SULLIVAN, M., BOLGER, G. & HOUSLAY, M.D. (1996). The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species which exhibit distinct kinetics of inhibition by the anti-depressant rolipram. J. Biol. Chem., 271, 31334-31344.
31. LAEMMLI, U.K. (1970). Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature, 222, 680-682.
32. LENHARD, J.M., KASSEL, D.B., ROCQUE, W.J., HAMACHER, L., HOLMES, W.D., PATEL, I., HOFFMAN, C. & LUTHER, M. (1996). Phosphorylation of a cAMP-specific phosphodiesterase (HSPDE4B2B) by mitogen-activated protein kinase. Biochem. J., 316, 751-758.
33. LIU, H. & MAURICE, D.H. (1999). Phosphorylation-mediated activation and translocation of the cyclic AMP-specific phosphodiesterase PDE4D3 by cyclic AMP-dependent protein kinase and mitogen-activated protein kinases: a potential mechanism allowing for the coordinated regulation of PDE4D activity and targeting. J. Biol. Chem., 274, 10557-10565.
34. MACKENZIE, S.J., BAILLIE, G.S., MCPHEE, I., BOLGER, G.B. & HOUSLAY, M.D. (2000). ERK2 MAP kinase binding, phosphorylation and regulation of PDE4D cAMP specific phosphodiesterases: the involvement of C-terminal docking sites and N-terminal UCR regions. J. Biol. Chem., 275, 16609-16617.
35. MACKENZIE, S.J. & HOUSLAY, M.D. (2000). The action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of CREB and p38 MAP kinase in U937 monocytic cells. Biochem. J., 347, 571-578.
36. MACKENZIE, S.J., YARWOOD, S.J., PEDEN, A.H., BOLGER, G.B., VERNON, R.J. & HOUSLAY, M.D. (1998). Stimulation of p70S6 kinase via a growth hormone controlled PI-3 kinase pathway leads to the activation of a PDE4 cAMP specific phosphodiesterases in 3T3-F442A preadipocytes. Proc. Natl. Acad. Sci. U.S.A., 95, 3549-3554.
37. MANGANIELLO, V.C., MURATA, T., TAIRA, M., BELFRAGE, P. & DEGERMAN, E. (1995). Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch. Biochem. Biophys., 322, 1-13.
38. MANNING, C.D., BURMAN, M., CHRISTENSEN, S.B., CIESLINSKI, L.B., ESSAYAN, D.M., GROUS, D., TORPHY, T.J. & BARNETTE, M.S. (1999). Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br. J. Pharmacol., 128, 1393-1398.
39. MARCHMONT, R.J. & HOUSLAY, M.D. (1980). Insulin controls the cyclic AMP-dependent phosphorylation of integral and peripheral proteins associated with the rat liver plasma membrane. FEBS Lett., 118, 18-24.
40. MCPHEE, I., YARWOOD, S.J., HUSTON, E., SCOTLAND, G., BEARD, M.B., ROSS, A.H., HOUSLAY, E.S. & HOUSLAY, M.D. (1999). Association with the src family tyrosyl kinase lyn triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B: consequences for rolipram inhibition. J. Biol. Chem., 274, 11796-11810.
41. NICHOLSON, C.D. & SHAHID, M. (1994). Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes-their potential utility in the therapy of asthma. Pulm. Pharmacol., 7, 1-17.
42. OWENS, R.J., LUMB, S., REES-MILTON, K., RUSSELL, A., BALDOCK, D., LANG, V., CRABBE, T., BALLESTEROS, M. & PERRY, M.J. (1997). Molecular cloning and expression of a human phosphodiesterase 4C. Cell. Signal., 9, 575-585.
43. ROGERS, D.F. & GIEMBYCZ, M.A. (1998). Asthma therapy for the 21st century. Trends Pharmacol. Sci., 19, 160-164.
44. SAXENA, M., WILLIAMS, S., TASKEN, K. & MUSTELIN, T. (1999). Crosstalk between cAMP-dependent kinase and MAP kinase through a protein tyrosine phosphatase. Nature Cell. Biol., 1, 305-311.
45. SCHMIDT, D., DENT, G. & RABE, K.F. (1999). Selective phosphodiesterase inhibitors for the treatment of bronchial asthma and chronic obstructive pulmonary disease. Clin. Exp. Allergy, 29 (Suppl. 2): 99-109.
46. SCHUDT, C., TENOR, H. & HATZELMANN, A. (1995). PDE isoenzymes as targets for anti-asthma drugs. Eur. Respir. J., 8, 1179-1183.
47. SETTE, C. & CONTI, M. (1996). Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase: involvement of serine 54 in the enzyme activation. J. Biol. Chem., 271, 16526-16534.
48. SETTE, C., IONA, S. & CONTI, M. (1994). The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation. J. Biol. Chem., 269, 9245-9252.
49. SEVETSON, B.R., KONG, X. & LAWRENCE, JR., J.C. (1993). Increasing cAMP attenuates activation of mitogen-activated protein kinase. Proc. Natl. Acad. Sci. U.S.A., 90, 10305-10309.
50. 2-adrenoreceptor desensitization. J. Biol. Chem., 273, 20575-20588.
51. SHAKUR, Y., WILSON, M., POOLEY, L., LOBBAN, M., GRIFFITHS, S.L., CAMPBELL, A.M., BEATTIE, J., DALY, C. & HOUSLAY, M.D. (1995). Identification and characterization of the type-IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum. Biochem. J., 306, 801-809.
52. SOUNESS, J.E. & RAO, S. (1997). Proposal for pharmacologically distinct conformers of PDE4. Cell. Signal., 9, 227-236.
53. SPINA, D., LANDELLS, L.J. & PAGE, C.P. (1998). The role of phosphodiesterase enzymes in allergy and asthma. Adv. Pharmacol., 44, 33-89.
54. SULLIVAN, M., OLSEN, A.S. & HOUSLAY, M.D. (1999). Genomic organisation of the human cyclic AMP specific phosphodiesterase PDE4C gene and its chromosomal localisation to 19p13.1, between the genes for RAB3A and JUND. Cell. Signal., 11, 735-742.
55. SULLIVAN, M., RENA, G., BEGG, F., GORDON, L., OLSEN, A.S. & HOUSLAY, M.D. (1998). Identification and characterization of the human homologue of the short PDE4A cAMP-specific phosphodiesterase RD1 (PDE4A1) by analysis of the human HSPDE4A gene locus located at chromosome 19p13.2. Biochem. J., 333, 693-703.
56. TEIXEIRA, M.M., GRISTWOOD, R.W., COOPER, N. & HELLEWELL, P.G. (1997). Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol. Sci., 18, 164-170.
57. THOMPSON, W.J. & APPLEMAN, M.M. (1971). Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry, 10, 311-316.
58. TIBBLES, L.A. & WOODGETT, J.R. (1999). The stress-activated protein kinase pathways. Cell. Mol. Life Sci., 55, 1230-1254.
59. TORPHY, T.J. (1998). Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am. J. Respir. Crit. Care Med., 157, 351-370.
60. TORPHY, T.J., BARNETTE, M.S., UNDERWOOD, D.C., GRISWOLD, D.E., CHRISTENSEN, S.B., MURDOCH, R.D., NIEMAN, R.B. & COMPTON, C.H. (1999). Ariflo™ (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm. Pharmacol. Ther., 12, 131-135.
61. WANG, P., WU, P., OHLETH, K.M., EGAN, R.W. & BILLAH, M.M. (1999). Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol. Pharmacol., 56, 170-174.
62. WARD, S.G. (1999). The complexities of CD28 and CTLA-4 signalling: P13K and beyond. Arch. Immunol. Ther. Exp. (Warsz.), 47, 69-75.
63. WU, J., DENT, P., JELINEK, T., WOLFMAN, A., WEBER, M.J. & STURGILL, T.W. (1993). Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′,5′-monophosphate. Science, 262, 1065-1069.